5,185 results match your criteria European journal of haematology[Journal]


The role of long non-coding RNAs in multiple myeloma.

Eur J Haematol 2019 Apr 15. Epub 2019 Apr 15.

Henan Institute of Haematology, Department of Hematology, Henan Cancer Hospital, The Affliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.

Multiple myeloma(MM) is still an incurable disease and its pathogenesis involves cytogenetics and epigenetics. In recent years, the roles of long non-coding RNAs (lncRNAs) in MM have been deeply studied by scholars. LncRNAs are defined as a class of nonprotein-coding transcripts greater than 200 nucleotides in length, which are involved in a large spectrum of biological processes, including proliferation, differentiation, apoptosis, invasion and chromatin remodeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13237DOI Listing
April 2019
1 Read

Clinical spectrum, evolution and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma.

Eur J Haematol 2019 Apr 15. Epub 2019 Apr 15.

Service de médecine interne, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est, Créteil, France.

Objective: Angioimmunoblastic T-cell lymphoma (AITL) are frequently associated with autoimmune cytopenia (AIC). Whether such patients have a particular phenotype and require particular management is unclear.

Method: AITL patients from the multicentric database of the Lymphoma Study Association presenting with AIC during disease course were included and matched to AITL patients without AIC (1/5 ratio). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13239DOI Listing
April 2019
1 Read

Variant specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.

Eur J Haematol 2019 Apr 15. Epub 2019 Apr 15.

Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark.

Objective: Molecular monitoring of treatment response in patients with chronic myelogenous leukemia is performed using the Europe Against Cancer (EAC) qPCR assay using the International Scale (IS). The assay amplifies both e13a2 and e14a2 BCR-ABL1 transcript variants. Observing distinct variant dependent amplification curves during qPCR, we aimed to determine if this affected quantitation of BCR-ABL1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13238DOI Listing
April 2019
1 Read

Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.

Eur J Haematol 2019 Apr 12. Epub 2019 Apr 12.

Department of Hematology and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo.

Objective: Prefibrotic/early primary myelofibrosis (pre-PMF) and essential thrombocythemia (ET) exhibited different features of bone marrow, however, this is not always easy to judge objectively, making pathologists' distinction often suboptimal. In the WHO 2008 criteria, pre-PMF was not defined as a subgroup of PMF; therefore, affected patients were at a higher risk of misdiagnosis with ET. In this study, we examined the prevalence of pre-PMF patients among those previously diagnosed with ET in Japan. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13236DOI Listing
April 2019
1 Read

Immunosuppressive therapy (IST) in adult patients with acquired aplastic anemia (AA): A single-center experience over the past 15 years.

Eur J Haematol 2019 Apr 11. Epub 2019 Apr 11.

Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Introduction: Immunosuppressive therapy (IST) with horse anti-thymocyte globulin (hATG) and cyclosporine (CsA) is considered one of the first-line therapy in patients (pts) with acquired aplastic anemia (AA).

Methods: In our single-center, retrospective analysis, response rates (RRs) to ATG at a minimum of six months were evaluated in 67 treatment-naïve (TN) AA pts (52.2% (35/67) females; median age 45 yrs (range 18 - 89 yrs) being treated at the West German Cancer Center at the Department of Hematology at the University Hospital of Essen between Apr 2000 until Dec 2015. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13235
Publisher Site
http://dx.doi.org/10.1111/ejh.13235DOI Listing
April 2019
5 Reads

Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.

Eur J Haematol 2019 Apr 10. Epub 2019 Apr 10.

Department of Hematology, Hospital del Mar, Barcelona, Spain.

Objective: To evaluate the role of N-terminal pro-brain-type natriuretic peptide (NT-pro-BNP) and a cardiovascular (CV) risk score named FRESCO for predicting anthracycline-induced cardiotoxicity (AIC) in diffuse large B-cell lymphoma (DLBCL).

Methods: 130 consecutive DLBCL patients treated in first-line with anthracycline-containing immunochemotherapy. Competitive risk between NT-proBNP, FRESCO and time to AIC was considered. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13234
Publisher Site
http://dx.doi.org/10.1111/ejh.13234DOI Listing
April 2019
2 Reads

Impact of Cyclosporine-A Concentration on Acute Graft-versus-Host Disease Incidence after Haploidentical Hematopoietic Cell Transplantation.

Eur J Haematol 2019 Apr 8. Epub 2019 Apr 8.

Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine (CRSA), F-75012, Paris, France.

Objectives: This retrospective study analyzed the impact of early cyclosporine-A (CsA) initiation (day - 3) on the risk of acute graft-versus-host disease (aGvHD) after haploidentical hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide.

Methods: Sixty-one consecutives patients who underwent Haplo-HCT were analyzed.

Results: At day +180, the cumulative incidences of grade II-IV and grade III-IV aGvHD were 39% and 18%, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13233DOI Listing
April 2019
1 Read

Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.

Eur J Haematol 2019 Apr 3. Epub 2019 Apr 3.

Dana-Farber Cancer Institute, Boston, MA, USA.

Objectives: To evaluate the safety and efficacy of maintenance therapy with the oral proteasome inhibitor ixazomib in patients with newly diagnosed multiple myeloma (NDMM) not undergoing transplantation.

Methods: Data were pooled from four NDMM phase I/II studies; patients received induction therapy with once- or twice-weekly ixazomib plus lenalidomide-dexamethasone (IRd), melphalan-prednisone (IMP), or cyclophosphamide-dexamethasone (ICd), followed by single-agent ixazomib maintenance, given at the last tolerated dose during induction, until disease progression, death, or unacceptable toxicity.

Results: 121 patients achieved stable disease or better after induction (weekly IRd, n = 25; twice-weekly IRd, n = 18; weekly or twice-weekly IMP, n = 35; weekly ICd, n = 43) and received ≥1 dose of ixazomib maintenance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13231DOI Listing
April 2019
4 Reads

Characteristics and Outcomes of Young Adults with Philadelphia negative Myeloproliferative Neoplasms.

Eur J Haematol 2019 Apr 2. Epub 2019 Apr 2.

Rappaport faculty of medicine, Technion, Haifa, Israel.

Objective: Approximately 10% of Philadelphia (Ph) negative myeloproliferative neoplasms (NPM) are diagnosed at young adulthood. We aim to define the features of this group.

Methods: A multicenter retrospective study, including patients 18-45 years of age, diagnosed with Ph negative MPN between 1985-2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13232DOI Listing
April 2019
6 Reads

Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants.

Eur J Haematol 2019 Mar 29. Epub 2019 Mar 29.

Messner Allogeneic Blood and Marrow Transplantation Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, Canada.

Introduction: We evaluated the combination of ATG and PTCy for GVHD prophylaxis in matched and mismatched unrelated PBSCTs for high risk hematological malignancies.

Methods: We treated 102 patients with reduced intensity conditioning (RIC) with fludarabine, busulfan and TBI 200 cGy. GVHD prophylaxis included rabbit ATG (thymoglobulin at total dose of 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13230DOI Listing
March 2019
2 Reads
2.066 Impact Factor

Addressing the room for improvement in management of acute promyelocytic leukemia.

Eur J Haematol 2019 Mar 19. Epub 2019 Mar 19.

Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.

Acute promyelocytic leukemia (APL) is highly curable. To achieve high cure rates, targeted therapy with retinoic acid (ATRA) must be started promptly at time of suspected diagnosis. Early death rates (EDRs, ≤30 days from diagnosis) differ markedly in patients treated on clinical trials compared to the general population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13229DOI Listing
March 2019
2 Reads

The role and contribution of clonality studies in the diagnosis of lymphoproliferative disorders.

Eur J Haematol 2019 Mar 7. Epub 2019 Mar 7.

Haematopathology and Oncology Diagnostics Service, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Objectives: To explore the frequency, context and diagnostic impact of B- and T-lymphocyte clonality assay use in the assessment of possible lymphoproliferative disorders at a central haematopathology diagnostics hub.

Methods: All cases reported by haematopathologists over a sixteen-month period were identified, n = 4462, and those which had clonality studies undertaken analysed further.

Results: Clonality studies were requested in 9% of cases, directly contributing to a diagnosis being made in 79%. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13228
Publisher Site
http://dx.doi.org/10.1111/ejh.13228DOI Listing
March 2019
6 Reads

Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.

Eur J Haematol 2019 Mar 4. Epub 2019 Mar 4.

Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Purpose: Sinonasal tract diffuse large B-cell lymphoma (SNT-DLBCL), a rare extranodal lymphoma, is not well characterized. We performed a population-based study to determine cell-of-origin, clinical presentation and impact of rituximab (R) and central nervous system (CNS) directed chemotherapy on survival.

Patients And Methods: Patients with SNT-DLBCL were identified from pathology databases. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13225
Publisher Site
http://dx.doi.org/10.1111/ejh.13225DOI Listing
March 2019
7 Reads

Frequency, characteristics, and outcome of PTLD after allo-SCT: A multicenter study from the Spanish group of blood and marrow transplantation (GETH).

Eur J Haematol 2019 Mar 3. Epub 2019 Mar 3.

Hospital Clínico de Valencia, Valencia, Spain.

Post-transplant lymphoproliferative disorder (PTLD) is an infrequent complication of allogeneic stem cell transplant (allo-SCT).

Aims: To estimate the frequency and management of PTLD in Spain and to identify prognostic factors influencing outcomes.

Methods: Multicenter, retrospective analysis of allo-SCT performed in 14 transplant units over a 15-year period. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13226
Publisher Site
http://dx.doi.org/10.1111/ejh.13226DOI Listing
March 2019
6 Reads

Home care of acute leukaemia patients: From active therapy to end-of-life and palliative care. The 3-year experience of a single centre.

Eur J Haematol 2019 May 15;102(5):424-431. Epub 2019 Mar 15.

Department of Hematology, Azienda Unità Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Purpose: The aim of the study was to evaluate the feasibility and the potential effects of the Haematological Home Care (HHC) programme for acute leukaemia (AL) patients, either in active chemotherapy or in the terminal phase of disease.

Methods: We retrospectively assessed a group of AL patients assisted at home in terms of number of hospitalisations, accesses to emergency department and place of death. We also used historical data to evaluate potential effects of HHC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13224DOI Listing

Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.

Eur J Haematol 2019 Feb 22. Epub 2019 Feb 22.

Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.

Objective: Despite long-standing safe and effective use of immunoglobulin replacement therapy (IgRT) in primary immunodeficiency, clinical data on IgRT in patients with secondary immunodeficiency (SID) due to B-cell lymphoproliferative diseases are limited. Here, we examine the correlation between approved IgRT indications, treatment recommendations, and clinical practice in SID.

Methods: An international online survey of 230 physicians responsible for the diagnosis of SID and the prescription of IgRT in patients with hematological malignancies was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13223DOI Listing
February 2019
3 Reads

Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.

Eur J Haematol 2019 May 7;102(5):416-423. Epub 2019 Mar 7.

Barts and The London School of Medicine and Dentistry, London, UK.

Background: Romiplostim is a thrombopoietin-mimetic peptibody for adult refractory chronic immune thrombocytopenia (ITP). We aimed to describe ITP patients receiving romiplostim, platelet counts and romiplostim usage in UK clinical practice.

Methods: This was a retrospective cohort study of patients in the UKITP Registry who received romiplostim between October 2009 and January 2015, including data up to 6 months before romiplostim initiation through follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13221DOI Listing
May 2019
2 Reads

Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma.

Eur J Haematol 2019 May 12;102(5):407-415. Epub 2019 Mar 12.

Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Objective: This prospective, observational, postmarketing surveillance was conducted to evaluate the safety and effectiveness of mogamulizumab, an anti-CC chemokine receptor 4 (CCR4) monoclonal antibody, in patients with CCR4-positive, relapsed or refractory (r/r) adult T-cell leukemia-lymphoma (ATL) in Japan.

Method: All patients were scheduled to receive intravenous infusions of mogamulizumab 1.0 mg/kg once weekly for 8 weeks, alone or in combination with other modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13220DOI Listing
May 2019
6 Reads

Stratification by MYC expression has prognostic impact in MYC translocated B-cell lymphoma-Identifies a subgroup of patients with poor outcome.

Eur J Haematol 2019 May 6;102(5):395-406. Epub 2019 Mar 6.

Department of Pathology, Herlev and Gentofte Hospital, Herlev, Denmark.

Objective: In patients with large B-cell lymphoma (LBCL) according to WHO, the prognostic significance of MYC translocation is still not sufficiently clarified. We therefore aimed to investigate whether prognostication could be improved in patients with MYC translocation positive LBCL by additional stratification according to MYC and BCL2 protein expression levels or MYC translocation partner gene as well as concurrent BCL2 and/or BCL6 translocation (DH).

Methods: From an unselected consecutive cohort of >600 patients with LBCL investigated with fluorescent in situ hybridization (FISH), 64 patients were diagnosed with MYC translocation positive LBCL and included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13219DOI Listing
May 2019
1 Read

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL-2 and/or BIM.

Eur J Haematol 2019 May 28;102(5):437-441. Epub 2019 Feb 28.

Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, Salzburg, Austria.

Acute myeloid leukemia (AML) is a disease of the elderly population and survival remains poor after failure of hypomethylating agents (HMA). The BCL-2 inhibitor venetoclax demonstrated activity as monotherapy and in combination with chemotherapy or HMA in AML. In this case series, patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA were treated with venetoclax within a named patient program at our tertiary cancer center in Salzburg, Austria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13218DOI Listing
May 2019
3 Reads

Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.

Eur J Haematol 2019 May 25;102(5):389-394. Epub 2019 Feb 25.

Hospital Clinic, IDIBAPS, Barcelona, Spain.

Objective: The presence of plasmacytomas (Ps) in patients with multiple myeloma (MM) is associated with a poor outcome, both in patients treated conventionally and in patients treated with novel agents. Two types of plasmacytomas have being recognized: paraskeletal plasmacytomas (PPs) and extramedullary plasmacytomas (EMPs), being the incidence of EMPs lower but with worse prognosis. Our aim has been to analyze the efficacy of the pomalidomide-dexamethasone combination in this patient profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13217DOI Listing
May 2019
1 Read

Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.

Eur J Haematol 2019 Apr 13;102(4):368-374. Epub 2019 Feb 13.

Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.

Objective: In individuals with cytogenetically normal (CN) AML, disease risk is estimated using molecular features such as the status of NPM1 and FLT3-ITD genes. However, data regarding the impact of NPM1 and FLT3-ITD status on hematopoietic stem cell transplant (HCT) outcomes are limited. We examined the effect of NPM1 and FLT3-ITD status on transplant outcomes in 131 CN AML patients transplanted at Princess Margaret Hospital between 2006 and 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13216DOI Listing
April 2019
11 Reads

Risks and challenges of CML management during pregnancy: Looking for a balanced decision.

Eur J Haematol 2019 Apr 12;102(4):378-379. Epub 2019 Feb 12.

National Research Center for Hematology, Moscow, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13215DOI Listing
April 2019
4 Reads

Caspofungin for primary antifungal prophylaxis after T-cell-replete haploidentical stem cell transplantation with post-transplant cyclophosphamide.

Eur J Haematol 2019 Apr 13;102(4):357-367. Epub 2019 Feb 13.

Bone Marrow Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy.

Objectives: T-cell-replete haploidentical stem cell transplantation (Haplo-SCT) with post-transplant cyclophosphamide (PT-Cy) is at high risk of invasive fungal infections (IFI), and anti-mold-active drug is required for primary antifungal prophylaxis (PAP) according to international guidelines. No data are available on the efficacy of caspofungin as PAP in this setting.

Methods: Here, we report our retrospective experience with 103 consecutive patients treated with caspofungin as PAP after Haplo-SCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13214DOI Listing
April 2019
15 Reads

Sequential liver and haematopoietic stem cell transplantation in a case of fulminant hepatitis associated liver failure and aplastic anaemia.

Eur J Haematol 2019 Apr 15;102(4):375-377. Epub 2019 Feb 15.

Hans Messner Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

The management of severe aplastic anaemia is particularly challenging when it occurs in the context of recent liver transplantation. Rapid identification of a suitable donor followed by allogeneic haematopoietic stem cell transplantation is the only curative option. This scenario is often complicated by potentially life-threatening infections that develop as a consequence of immunosuppression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13213DOI Listing
April 2019
6 Reads

Single versus double-unit transfusion: Safety and efficacy for patients with hematologic malignancies.

Eur J Haematol 2019 May 25;102(5):383-388. Epub 2019 Feb 25.

Alexander B. Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, West Virginia.

Objectives: Although hemoglobin thresholds for red blood cell (RBC) transfusion have decreased, double-unit RBC transfusion practices persist. We studied the effects switching from predominantly double-unit to single-unit RBC transfusions had on utilization and clinical outcomes for malignant hematology patients.

Methods: Retrospective chart review compared malignant hematology patients before and after implementing single-unit RBC transfusion policy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13211
Publisher Site
http://dx.doi.org/10.1111/ejh.13211DOI Listing
May 2019
4 Reads

Insight into the complex pathophysiology of sickle cell anaemia and possible treatment.

Eur J Haematol 2019 Apr 21;102(4):319-330. Epub 2019 Feb 21.

Department of Paediatric Haematology, Our Lady's Children's Hospital, Dublin, Ireland.

Sickle cell anaemia (SCA) is the consequence of abnormal haemoglobin production due to an inherited point mutation in the β-globin gene. The resulting haemoglobin tetramer is poorly soluble when deoxygenated, and when this is prolonged, intracellular gelation of sickle haemoglobin occurs, followed by haemoglobin polymerisation. If many cycles of sickling and unsickling occur, the red cell membrane will be disrupted leading to haemolysis and vaso-occlusive events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13212DOI Listing
April 2019
8 Reads
2.066 Impact Factor

Corrigendum.

Authors:

Eur J Haematol 2019 Jan 20. Epub 2019 Jan 20.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13195DOI Listing
January 2019
2 Reads

Bleeding assessment in female patients with the Hermansky-Pudlak syndrome-A case series.

Eur J Haematol 2019 May 6;102(5):432-436. Epub 2019 Mar 6.

Department of Surgery, School of Medicine, University of Puerto Rico, San Juan, Puerto Rico.

Introduction: The Hermansky-Pudlak syndrome (HPS) is an autosomal recessive rare disorder characterized by oculocutaneous albinism, bleeding diathesis, chronic granulomatous colitis and/or pulmonary fibrosis. HPS is the most common single-gene disorder in Puerto Rico with a prevalence of 1:1,800 in the Northwest of the island. Risk of menorrhagia and post-partum hemorrhage (PPH) in cases of women with HPS have been described in the medical literature, but data regarding comprehensive description of bleeding diathesis remains lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13210DOI Listing
May 2019
3 Reads

Common oral diseases in allogeneic haematopoietic stem cell transplantation (HSCT) recipients pre-HSCT.

Eur J Haematol 2019 Apr 30;102(4):351-356. Epub 2019 Jan 30.

Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Objectives: The purpose of this study was to compare the prevalence of common oral diseases between allogeneic haematopoietic stem cell transplantation (HSCT) recipients and healthy controls.

Materials And Methods: A total of 143 adult allogeneic HSCT recipients who were treated for haematological malignancies between 2008 and 2016 were included in the study. The HSCT recipients were age and sex matched with healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13209DOI Listing
April 2019
2 Reads

The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: A review of the literature.

Eur J Haematol 2019 Apr 7;102(4):312-318. Epub 2019 Feb 7.

The Division of Hematology & Oncology, School of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.

Direct oral anticoagulants (DOACs) have been shown to be superior to vitamin K antagonists (VKAs) in regards to safety and efficacy in numerous clinical trials and are now the preferred oral anticoagulant by multiple professional societies. However, patients with significant levels of organ dysfunction were excluded from all major clinical trials, leaving the clinical benefit in these subsets uncertain. Patients with chronic kidney disease (CKD) specifically often require anticoagulation for acute or long-term indications such as venous thromboembolism, atrial fibrillation, or mechanical heart valves. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13208DOI Listing
April 2019
5 Reads

Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.

Eur J Haematol 2019 Apr 5;102(4):341-350. Epub 2019 Feb 5.

Astellas Pharma US, Inc., Northbrook, Illinois.

Objectives: To assess real-world treatment patterns and healthcare resource utilization (HRU) among patients with FLT3-mutated (FLT3 ) and FLT3-wild-type (FLT3 ) acute myeloid leukemia (AML).

Methods: Data were abstracted from medical charts of patients with AML from 10 countries. Patients were grouped based on their FLT3 mutation status, age (18-64 or ≥65), and whether they were newly diagnosed (ND) or relapsed/refractory (R/R). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13205DOI Listing
April 2019
3 Reads

Interaction of increasing ICU survival and admittance policies in patients with hematologic neoplasms: A single center experience with 304 patients.

Eur J Haematol 2019 Mar 17;102(3):265-274. Epub 2019 Jan 17.

Department of Haematology, Oncology and Clinical Immunology, Medical Faculty, University Hospital Duesseldorf, Duesseldorf, Germany.

Objective: We evaluated the development of ICU survival of patients with hematopoietic malignancies and discussed changes in admittance policies.

Method: We compared 166 patients treated between 2009 and 2012 with 138 patients treated between 2013 and 2016. Patient characteristics and outcome were analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13206DOI Listing
March 2019
4 Reads

Molecular pathogenesis of myelodysplastic syndromes with deletion 5q.

Eur J Haematol 2019 Mar 16;102(3):203-209. Epub 2019 Jan 16.

Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

The molecular pathogenesis of deletion 5q (del(5q)) myelodysplastic syndrome (MDS) has recently been realized as a result of major advances in our understanding of the mechanisms responsible for clinical phenotype. Identification of commonly deleted genes such as RPS14, miRNA-145, HSPA9, CD78, and CSNK1a1 have elucidated the precise biological changes responsible for the anemia, leukopenia, and thrombocytosis that characterizes del(5q) MDS and highlighted the importance of allelic haploinsufficiency in the hematological phenotype. Recent elegant investigations have also identified a critical role of innate immune signaling in del(5q) pathogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13207DOI Listing
March 2019
4 Reads

Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin.

Eur J Haematol 2019 Mar 9;102(3):256-264. Epub 2019 Jan 9.

Division of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Objectives: To establish the optimal strategy for haploidentical hematopoietic stem cell transplantation (HSCT).

Methods: We performed a prospective study on haploidentical HSCT using low-dose alemtuzumab. Alemtuzumab was added at 0. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13204
Publisher Site
http://dx.doi.org/10.1111/ejh.13204DOI Listing
March 2019
16 Reads

Haematological malignancy: Are we measuring what is important to patients? A systematic review of quality-of-life instruments.

Eur J Haematol 2019 Apr 14;102(4):279-311. Epub 2019 Feb 14.

School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK.

The wide range of health-related quality-of-life (HRQoL) instruments used in haematology makes it challenging for haematologists and other care team members in practice to select, use and understand the scoring system and finally interpret the results. The main objectives of this study were to: (a) provide a comprehensive list of quality-of-life issues important to patients suffering from haematological malignancies, identified through the literature; (b) provide a list of health-related quality-of-life (HRQoL) instruments used in haematological malignancies in both daily clinical practice and research; and (c) evaluate the relevance and comprehensibility of the identified instruments in haematological malignancies. Systematic literature review of two databases, followed by addition of articles by manual searching, was carried out. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/ejh.13203
Publisher Site
http://dx.doi.org/10.1111/ejh.13203DOI Listing
April 2019
11 Reads

Corrigendum.

Authors:

Eur J Haematol 2019 Jan 19;102(1):99. Epub 2018 Nov 19.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13181DOI Listing
January 2019
2 Reads

Invasive fungal disease in patients undergoing umbilical cord blood transplantation after myeloablative conditioning regimen.

Eur J Haematol 2019 Apr 12;102(4):331-340. Epub 2019 Feb 12.

Department of Hematology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Objective: Characteristics and risk factors (RFs) of invasive fungal disease (IFD) have been little studied in the setting of umbilical cord blood transplantation (UCBT).

Method: We retrospectively included 205 single-unit myeloablative UCBT recipients with a median follow-up of 64 months.

Results: Fifty-six episodes of IFD were observed in 48 patients (23%) at a median time of 123 days after stem cell infusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13202DOI Listing
April 2019
6 Reads

Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study.

Eur J Haematol 2019 Feb 28;102(2):182-190. Epub 2018 Nov 28.

Department of Hematology, Rigshospitalet, Copenhagen, Denmark.

Objectives: Infections pose the greatest risk of early death in patients with Multiple Myeloma. However, few studies have analyzed the risk factors for infections in Multiple Myeloma patients. The aim of this study was to analyze the risk factors infections within a population-based MM cohort. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13190
Publisher Site
http://dx.doi.org/10.1111/ejh.13190DOI Listing
February 2019
8 Reads

Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group.

Eur J Haematol 2019 Mar 1;102(3):235-240. Epub 2019 Jan 1.

Hematology Section, Specialist Medicine, NU Hospital Group, Uddevalla, Sweden.

Objectives: The study investigates the hypothesis that inflammation in myelofibrosis (MF) like in myeloma and lymphoma, may disturb iron distribution and contribute to anaemia.

Methods: A cross-sectional study of 80 MF and 23 ET patients was performed.

Results: About 35% of anaemic MF patients had functional iron deficiency (FID) with transferrin saturation <20 and normal or elevated S-ferritin (<500 µg/L). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13198DOI Listing
March 2019
13 Reads

Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvement.

Eur J Haematol 2019 Mar 20;102(3):241-250. Epub 2019 Jan 20.

Department of Haematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.

Objectives: The GMALL-B-ALL/NHL2002 protocol is effective in Burkitt lymphoma/leukemia (BL). Its role in other aggressive lymphomas and in patients with simultaneous central nervous system (CNS) and peripheral involvement is unclear.

Methods: This is a retrospective outcome analysis in 76 patients with BL (n = 26), B-lymphoblastic lymphoma (B-LBL; n = 3), diffuse large B-cell lymphoma (DLBCL; n = 31), mantle cell lymphoma (MCL; n = 6), transformed B-cell non-Hodgkin lymphomas (tB-NHL; n = 7), and T-cell NHL (T-NHL; n = 3) treated with the GMALL-B-ALL/NHL2002 protocol. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13199DOI Listing
March 2019
37 Reads

CTLA-4 polymorphism rs231775: Influence on relapse and survival after allogeneic hematopoietic stem cell transplantation in childhood.

Eur J Haematol 2019 Mar 7;102(3):251-255. Epub 2019 Jan 7.

Department of Pediatrics, Jena University Hospital, Jena, Germany.

Objective: Relapse following allogeneic hematopoietic stem cell transplantation (HSCT) is still linked to a poor prognosis. Mainly, donor`s T-cells mediate the graft-versus-leukemia effect. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule which down-regulates T-cell activation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13200DOI Listing
March 2019
13 Reads

Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms.

Eur J Haematol 2019 Mar 10;102(3):227-234. Epub 2019 Jan 10.

Department of Haematology, Odense University Hospital, Odense, Denmark.

Objective: Pulmonary hypertension (PH) has been reported to be associated with myeloproliferative neoplasms (MPN), affecting 5%-48% of MPN patients. With the aims to describe the prevalence of PH in Ph-MPN patients and explore the cause in identified subjects, we performed a prospective cohort study of Ph-MPN patients.

Method: Transthoracic echocardiography (TTE) was performed on all patients. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13197
Publisher Site
http://dx.doi.org/10.1111/ejh.13197DOI Listing
March 2019
20 Reads

Bone marrow mononuclear cell telomere length in acute myeloid leukaemia and high-risk myelodysplastic syndrome.

Eur J Haematol 2019 Mar 22;102(3):218-226. Epub 2019 Jan 22.

Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.

Objective: Short telomere length is a known risk factor for developing clonal haematopoietic stem cell disorders, probably due to chromosomal instability. We tested the hypotheses that bone marrow mononuclear cell telomere length change from diagnosis through chemotherapy-induced remission and relapse, and that long telomere length is associated with low risk of relapse and all-cause mortality in patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome.

Methods: We measured telomere length in bone marrow mononuclear cells from 233 patients at diagnosis, 112 patients at chemotherapy-induced remission and 58 patients at relapse of disease. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13196
Publisher Site
http://dx.doi.org/10.1111/ejh.13196DOI Listing
March 2019
3 Reads

Current practices in the management of adenovirus infection in allogeneic hematopoietic stem cell transplant recipients in Europe: The AdVance study.

Eur J Haematol 2019 Mar 11;102(3):210-217. Epub 2019 Jan 11.

Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.

Objective: Adenovirus (AdV) infections are potentially life-threatening for allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. The AdVance study aimed to evaluate the incidence, management, and outcomes of AdV infections in European allo-HCT recipients.

Methods: As part of the study, physician surveys were conducted to determine current AdV screening and treatment practices at their center. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13194
Publisher Site
http://dx.doi.org/10.1111/ejh.13194DOI Listing
March 2019
18 Reads

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.

Eur J Haematol 2019 Feb 6;102(2):111-122. Epub 2018 Dec 6.

Foundation IRCCS Cà Granda, Maggiore Hospital Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against FVIII/FIX face an increased risk of bleeding, and the likelihood of early development of progressive arthropathy, alongside higher treatment-related costs. Bypassing agents can be used to prevent and control bleeding, as well as the recently licensed prophylaxis, emicizumab, but their efficacy is less predictable than that of factor replacement therapy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13193
Publisher Site
http://dx.doi.org/10.1111/ejh.13193DOI Listing
February 2019
33 Reads

Back to the future: Treatment-free remission and pregnancy in chronic myeloid leukemia.

Eur J Haematol 2019 Feb 29;102(2):197-199. Epub 2018 Nov 29.

Memorial Sloan Kettering Cancer Center, New York City, New York.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13192
Publisher Site
http://dx.doi.org/10.1111/ejh.13192DOI Listing
February 2019
18 Reads

CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.

Eur J Haematol 2019 Feb 23;102(2):191-196. Epub 2018 Nov 23.

Department of Laboratory Molecular Genetics of Hematology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.

Objective: Primary vitreoretinal lymphoma (PVRL) is a rare type of lymphoma wherein the lesions are limited to the eyes. PVRL is difficult to diagnose because of the challenges related to obtaining sufficient samples for biopsy. Moreover, PVRL has poor outcomes and often leads to the development of central nervous system (CNS) lesions during its course. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13191
Publisher Site
http://dx.doi.org/10.1111/ejh.13191DOI Listing
February 2019
22 Reads

Molecular pathogenesis of acquired aplastic anemia.

Eur J Haematol 2019 Feb 18;102(2):103-110. Epub 2018 Dec 18.

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.

The application of next-generation sequencing (NGS) has enhanced our understanding of the genetic landscape in acquired aplastic anemia (AA). Parallel progress has been in addressing aspects underlying immune dysregulation in disease pathogenesis. Novel insights into the molecular and biologic mechanisms have led to a shift in the paradigm of AA, from a solely autoimmune pathogenic concept toward its recognition as a multifaceted pathophysiology characterized by cytogenetic abnormalities, recurrent somatic mutations, telomere attrition, and immune dysregulation. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13182
Publisher Site
http://dx.doi.org/10.1111/ejh.13182DOI Listing
February 2019
15 Reads